XZXiaochen Zhang

Xiaochen Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaochen Zhang has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Health insurance and end-of-life healthcare expenditures: evidence from Chinese Longitudinal Healthy Longevity Survey

    by Liangjun Song, Xiaochen Zhang, Mingqi Wang

    The terminal stage of life accounts for a substantial share of healthcare expenditures over the life course. Using data from the Chinese Longitudinal Healthy Longevity Survey (2005–2018), this study examines the impact of health insurance coverage on healthcare spending during the last year of life. To address potential selection bias, we first estimate the probability of insurance coverage using logistic regression and then compare expenditure patterns between insured and uninsured populations through propensity score matching. We further conduct rural–urban and regional subgroup analyses to explore heterogeneity in insurance effects. Our results reveal significant differences in medical expenditures associated with insurance utilization, while no significant disparities are observed in nursing care costs across groups. These findings provide new evidence about increasing healthcare spending in a non-Western context, and call for a more balanced health system to reduce inequalities in end-of-life healthcare due to insurance coverage among the elderly.


  • Open Access

    Economic Evaluation of a Multicomponent mHealth Intervention for Stroke Management in Rural China: Cluster-Randomized Trial With 6-Year Follow-Up

    by Bolu Yang, Enying Gong, Xingxing Chen, Jie Tan, Nicholas Peoples, Yuhan Li, Jiayu Cai, Yan Li, Brian Oldenburg, Chen Chen, et al.

    Background: To bridge the gap between clinical guidelines and suboptimal stroke management in rural settings, we conducted an implementation trial using evidence-based, mobile health–enabled strategies to empower primary care providers in rural China. The system-integrated and digital technology–enabled model of care (SINEMA) model was shown to significantly reduce blood pressure and mortality among people with stroke in rural China. Objective: This study aimed to evaluate the cost-effectiveness of the SINEMA intervention within both the active trial and the post-trial observational periods and its budget impact for potential nationwide scalability. Methods: In the cluster-randomized implementation trial (the SINEMA trial), 50 villages were randomized to either a 1-year intervention (2017-2018) or usual care, with 1299 patients with stroke followed up until 2022-2023—6 years after the trial baseline. The incremental cost-effectiveness ratios (ICER) for systolic blood pressure reduction and quality-adjusted life year gains were estimated from a health sector perspective. Both probabilistic and deterministic sensitivity analyses were conducted to assess the robustness of the findings. Additionally, a budget impact analysis was performed from a public payer perspective to estimate the per-capita and total costs of national scale-up under 2 scenarios: a standalone intervention and integration into the existing basic public health service system. Results: The ICER per 1 mmHg systolic blood pressure reduction was $8.4 for the within-trial estimation. The ICER per quality-adjusted life year gained was $837.9 within-trial and $727.9 post-trial, both highly cost-effective relative to any commonly adopted thresholds and robust in sensitivity analyses. The first-year budget impact ranged from $115.6 million to $197.7 million in the 2 scenarios, reducing to $46.6 million to $78.7 million by year 5, with a per-capita cost of $0.03-$0.06. Conclusions: Our findings demonstrate that the SINEMA intervention was cost-effective during the trial period and remained so throughout the 6-year sustainability observation period. These results highlight the potential of adopting similar health system–integrated, mobile health–enabled strategies to enhance the management of stroke and other chronic diseases in resource-limited settings. Trial Registration: ClinicalTrials.gov NCT0318585, ClinicalTrials.gov NCT05792618; https://clinicaltrials.gov/study/NCT03185858 and https://clinicaltrials.gov/study/NCT05792618 International Registered Report Identifier (IRRID): RR2-10.3389/fneur.2023.1145562


  • Open Access

    Economic Evaluation of a Multicomponent mHealth Intervention for Stroke Management in Rural China: Cluster-Randomized Trial With 6-Year Follow-Up (Preprint)

    by Bolu Yang, Enying Gong, Xingxing Chen, Jie Tan, Nicholas Peoples, Yuhan Li, Jiayu Cai, Yan Li, Brian Oldenburg, Chen Chen, et al.

    BACKGROUND To bridge the gap between clinical guidelines and suboptimal stroke management in rural settings, we conducted an implementation trial using evidence-based, mobile health–enabled strategies to empower primary care providers in rural China. The system-integrated and digital technology–enabled model of care (SINEMA) model was shown to significantly reduce blood pressure and mortality among people with stroke in rural China. OBJECTIVE This study aimed to evaluate the cost-effectiveness of the SINEMA intervention within both the active trial and the post-trial observational periods and its budget impact for potential nationwide scalability. METHODS In the cluster-randomized implementation trial (the SINEMA trial), 50 villages were randomized to either a 1-year intervention (2017-2018) or usual care, with 1299 patients with stroke followed up until 2022-2023—6 years after the trial baseline. The incremental cost-effectiveness ratios (ICER) for systolic blood pressure reduction and quality-adjusted life year gains were estimated from a health sector perspective. Both probabilistic and deterministic sensitivity analyses were conducted to assess the robustness of the findings. Additionally, a budget impact analysis was performed from a public payer perspective to estimate the per-capita and total costs of national scale-up under 2 scenarios: a standalone intervention and integration into the existing basic public health service system. RESULTS The ICER per 1 mmHg systolic blood pressure reduction was $8.4 for the within-trial estimation. The ICER per quality-adjusted life year gained was $837.9 within-trial and $727.9 post-trial, both highly cost-effective relative to any commonly adopted thresholds and robust in sensitivity analyses. The first-year budget impact ranged from $115.6 million to $197.7 million in the 2 scenarios, reducing to $46.6 million to $78.7 million by year 5, with a per-capita cost of $0.03-$0.06. CONCLUSIONS Our findings demonstrate that the SINEMA intervention was cost-effective during the trial period and remained so throughout the 6-year sustainability observation period. These results highlight the potential of adopting similar health system–integrated, mobile health–enabled strategies to enhance the management of stroke and other chronic diseases in resource-limited settings. CLINICALTRIAL ClinicalTrials.gov NCT0318585, ClinicalTrials.gov NCT05792618; https://clinicaltrials.gov/study/NCT03185858 and https://clinicaltrials.gov/study/NCT05792618 INTERNATIONAL REGISTERED REPORT RR2-10.3389/fneur.2023.1145562

  • Open Access

    Long-term mortality outcome of a primary care-based mobile health intervention for stroke management: Six-year follow-up of a cluster-randomized controlled trial

    by Xingxing Chen, Enying Gong, Jie Tan, Elizabeth L. Turner, John A. Gallis, Shifeng Sun, Siran Luo, Fei Wu, Bolu Yang, Yutong Long, et al.

    Background: Despite growing evidence of primary care-based interventions for chronic disease management in resource-limited settings, long-term post-trial effects remain inconclusive. We investigated the association of a 12-month system-integrated technology-enabled model of care (SINEMA) intervention with mortality outcomes among patients experiencing stroke at 6-year post-trial. Methods and findings: This study (clinicltiral.gov registration number: NCT05792618) is a long-term passive observational follow-up of participants and their spouse of the SINEMA trial (clinicaltrial.gov registration number: NCT03185858). The original SINEMA trial was a cluster-randomized controlled trial conducted in 50 villages (clusters) in rural China among patients experiencing stroke during July 2017–July 2018. Village doctors in the intervention arm received training, incentives, and a customized mobile health application supporting monthly follow-ups to participants who also received daily free automated voice-messages. Vital status and causes of death were ascertained using local death registry, standardized village doctor records, and verbal autopsy. The post-trial observational follow-up spanned from 13- to 70-months post-baseline (up to April 30, 2023), during which no intervention was requested or supported. The primary outcome of this study was all-cause mortality, with cardiovascular and stroke cause-specific mortality also reported. Cox proportional hazards models with cluster-robust standard errors were used to compute hazard ratios (HRs) and 95% confidence intervals (95% CIs), adjusting for town, age, and sex in the main analysis model. Analyses were conducted on an intention-to-treat basis. Of 1,299 patients experiencing stroke (mean age 65.7 years, 42.6% females) followed-up to 6 years, 276 (21.2%) died (median time-to-death 43.0 months [quantile 1–quantile 3: 26.7–56.8]). Cumulative incidence of all-cause mortality was 19.0% (121 among 637) in the intervention arm versus 23.4% (155 among 662) in the control arm (HR 0.73; 95% CI 0.59, 0.90; p = 0.004); 14.4% versus 17.7% (HR 0.73; 95% CI 0.58, 0.94; p = 0.013) for cardiovascular cause-specific mortality; and 6.0% versus 7.9% (HR 0.71; 95% CI 0.44, 1.15; p = 0.16) for stroke cause-specific mortality. Although multisource verification was used to verify the outcomes, limitations exist as the survey- and record-matching-based nature of the study, unavailability of accurate clinical diagnostic records for some cases and the potential confounders that may influence the observed association on mortality. Conclusions: Despite no observed statistically difference on stroke cause-specific mortality, the 12-month SINEMA intervention, compared with usual care, significantly associated with reduced all-cause and cardiovascular cause-specific mortality during 6 years of follow-up, suggesting potential sustained long-term benefits to patients experiencing stroke.


  • Open Access

    Navigating the implementation gap for Trastuzumab's journey from health insurance to patient access: a preliminary study in a hospital in China

    by Xingxia Yang, Yufei Jia, Jianhong Xu, Qin Zhou, Qian Long, Yi Yang, Yunguo Liu, Juanying Zhu, Xiaochen Zhang


  • Open Access

    Trastuzumab Accessibility and Utilization for Breast Cancer Treatment in an eastern prefecture-level city in China: Does health insurance coverage matter?

    by Xingxia Yang, Yufei Jia, Jianhong Xu, Qin Zhou, Qian Long, Yi Yang, Yunguo Liu, Juanying Zhu, Xiaochen Zhang

    Background Trastuzumab, a monoclonal antibody for breast cancer, faces global accessibility challenges, especially in low- and middle-income countries, primarily due to high costs. This study examines the impact of medical insurance policy changes and price reductions on Trastuzumab utilization in China, using JX city as a case study, to provide insights into improving drug accessibility and affordability. Methods This retrospective study investigated Trastuzumab utilization among HER2-positive breast cancer patients at a tertiary hospital from May 2013 to December 2022 in JX, a prefecture-level city located in eastern China. Patients were stratified based on their CerbB2 indicator. Patients with a 2 + CerbB2 status require further FISH testing to confirm HER2 expression for Trastuzumab eligibility, while patients with a 3 + CerbB2 status directly qualifies for the treatment. We analyzed the utilization rates of FISH test and Trastuzumab using logistic regressions, identifying factors that influence their usage. Results 766 patients were included in this study. The utilization rate of Trastuzumab among patients with CerbB2 3 + rose from 40.40–77.94% in September 2017 following the expansion of insurance coverage, and further increased to 90.41% after a price reduction in 2020. The FISH test was not covered by health insurance, and it was not available in the local hospital until Trastuzumab became available in JX city. For patients with CerbB2 2+, the proportion undergoing the FISH test increased dramatically from 8.89–82.08% after the price reduction in 2020. The mere inclusion into basic medical insurance, regardless of insurance types, significantly increased the utilization of Trastuzumab and the FISH test. However, rural patients in JX city are still facing financial burdens with Trastuzumab's out-of-pocket cost accounting for 62.9% of their annual disposable income in 2020. Conclusions Our findings indicate that expanding insurance coverage and reducing the price significantly increased Trastuzumab utilization. Additionally, improving the accessibility of the FISH test plays a crucial role in enhancing the uptake of Trastuzumab among eligible patients. These insights are essential for informing policies in China and other low- and middle-income countries towards achieving universal health coverage.

  • Open Access

    How Does an Environmental Amenity Attract Voluntary Migrants? Evidence from Ambient Air Quality in China

    by Moon Joon Kim, Xiaolin Xie, Xiaochen Zhang

    Recent studies have shown that air quality is an important amenity for population relocation in China. However, much of Chinese internal migration occurs due to non-discretionary reasons, such as government policies, family considerations, and military personnel reassignments. As such, estimates of the impact of environmental amenities on migration that do not control for migration reasons may be biased. Using the 2015 China Migrants Dynamic Survey, this paper estimates the impact of ambient air pollution on voluntary migration to other provinces for work. We find that more polluted days (air quality index (AQI) > 150) at the original residence leads to a significant increase in labor out-migration to a province with better air quality, providing evidence of the current migration trend leading to declining populations in China’s megacities. Our findings indicate that environmental migration is more favored among households that are less educated, are older, work overtime, and have lower income, suggesting that environmental migration may result from environmental health inequalities in socially disadvantaged families.